Status:
TERMINATED
Effect of Combination Non Steroidal Antiinflammatory Drugs and Narrowband UVB Treatment in Non-Photoadapters
Lead Sponsor:
Henry Ford Health System
Conditions:
Vitiligo
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
Narrow band UVB phototherapy is the mainstay of therapy for vitiligo. However, about 1/3 of patients cannot respond to phototherapy. The objective of this study is to determine if the use of ibuprofen...
Detailed Description
Vitiligo is an acquired disorder of pigmentation. The depigmented regions present as white macules and patches and can occur at any age. The vitiligo patches may be asymptomatic, pruritic or may sunbu...
Eligibility Criteria
Inclusion
- Patients should have a diagnosis of vitiligo.
- Patients who are identified as nonphotoadapters (those who cannot increase NBUVB dose past 400 mJ/cm2) will be recruited for the study
Exclusion
- Patients with the daily ibuprofen use, history of renal disease, cardiac disease, gastric uler and bleeding disorder will be excluded from the study. Patients with a history of lupus erythematosus and other photosensitivity disorders will be excluded from the study.
Key Trial Info
Start Date :
August 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 24 2016
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT05256147
Start Date
August 1 2015
End Date
May 24 2016
Last Update
February 25 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Henry Ford Dermatology
Detroit, Michigan, United States, 48202